Fig. 4

Forest plots of serious adverse events comparing tocilizumab combination therapy (TCZ COMBI ) with tocilizumab monotherapy (TCZ MONO ) (a), TCZ COMBI with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) (b) and TCZMONO with a csDMARD (c)